Breakthrough personalized mRNA vaccine cuts melanoma recurrence risk by 50% when combined with Keytruda, Moderna CEO reveals ...

Mount Sinai researchers have identified a cellular mechanism linking infections from influenza A viruses (IAVs) to ...

Ethris GmbH, a clinical-stage biotechnology company pioneering next-generation RNA therapeutics and vaccines, and the German Center for Infection Research (Deutsches Zentrum für Infektionsforschung, ...

In early February 2026, the U.S. District Court for the District of Delaware denied Moderna’s bid for summary judgment in a multi-billion-dollar patent infringement case brought by Arbutus Biopharma ...

A federal judge just invoked Star Trek in a $5 billion patent ruling against Moderna. Here is why the mRNA giant is heading to a high-stakes jury trial.

In a comparison of COVID-19 vaccines, the mRNA vaccine sustained higher anti-S IgG, while the Ad-vector had superior neutralizing capacity.

One panelist accused the F.D.A. of withholding data on potential harms. The advisers also are reviewing research on vaccines ...

Despite Sanofi CEO Paul Hudson’s confidence in vaccines, the French pharma has cut at least one mRNA flu shot program.

Two and a half years after Sanofi unveiled to investors a revamped strategy to create an mRNA seasonal flu vaccine, Fierce Biotech has learned that the French pharma has put this pipeline on ice.

Moderna shares are down on Monday, pulling back following a recent report highlighting its latest cancer trial results.

University of Oklahoma researchers have created a new drug delivery system that helps cancer cells take in much more of a ...

Five-year data from the KEYNOTE–942 trial show that the personalized mRNA cancer vaccine intismeran autogene, combined with ...